fair enough - I think manufacturing shouldn’t be an issue. It clearly has the advantage in that area. I think it’s more the logistics and supply chain of the drug that will make it tricky to commercialise. It has a longer half life but it is still time sensitive.
Personally, it’s not something that I know too much about but that would definitely be something Pharma companies will look for as well as the manufacturing.
Research/Valuation, page-5
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.67 |
Change
0.070(1.52%) |
Mkt cap ! $1.452B | |||
| Open | High | Low | Value | Volume |
| $4.68 | $4.95 | $4.60 | $9.186M | 1.917M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2515 | $4.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.70 | 25000 | 2 |
View Market Depth
| Last trade - 16.10pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$4.67 |
Change
0.070 ( 2.33 %) |
||||
| Open | High | Low | Volume | ||
| $4.67 | $4.95 | $4.60 | 138383 | ||
| Last updated 15.59pm 30/05/2024 ? | |||||
| CU6 (ASX) Chart |